Rhabdomyosarcoma-Pipeline Review, H1 2015

Rhabdomyosarcoma-Pipeline Review, H1 2015

  • Products Id :- GMDHC6429IDB
  • |
  • Pages: 87
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Rhabdomyosarcoma-Pipeline Review, H1 2015


Global Markets Direct's, 'Rhabdomyosarcoma-Pipeline Review, H1 2015', provides an overview of the Rhabdomyosarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Rhabdomyosarcoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Rhabdomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Rhabdomyosarcoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Rhabdomyosarcoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Rhabdomyosarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Rhabdomyosarcoma Overview 6

Therapeutics Development 7

Pipeline Products for Rhabdomyosarcoma-Overview 7

Pipeline Products for Rhabdomyosarcoma-Comparative Analysis 8

Rhabdomyosarcoma-Therapeutics under Development by Companies 9

Rhabdomyosarcoma-Therapeutics under Investigation by Universities/Institutes 10

Rhabdomyosarcoma-Pipeline Products Glance 11

Clinical Stage Products 11

Rhabdomyosarcoma-Products under Development by Companies 12

Rhabdomyosarcoma-Products under Investigation by Universities/Institutes 13

Rhabdomyosarcoma-Companies Involved in Therapeutics Development 14

Bellicum Pharmaceuticals, Inc. 14

Boehringer Ingelheim GmbH 15

Celgene Corporation 16

Eisai Co., Ltd. 17

GlaxoSmithKline plc 18

Merrimack Pharmaceuticals, Inc. 19

Neotropix, Inc. 20

Novartis AG 21

Rhabdomyosarcoma-Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Target 23

Assessment by Mechanism of Action 25

Assessment by Route of Administration 27

Assessment by Molecule Type 29

Drug Profiles 31

afatinib-Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

Cell Therapy for GD2 Expressing Solid Tumors-Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

celyvir-Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

E-7438-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

everolimus-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

irinotecan sucrosofate liposomal-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

NTX-010-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

paclitaxel albumin bound-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

pazopanib hydrochloride-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

Rhabdomyosarcoma-Recent Pipeline Updates 58

Rhabdomyosarcoma-Dormant Projects 84

Rhabdomyosarcoma-Discontinued Products 85

Appendix 86

Methodology 86

Coverage 86

Secondary Research 86

Primary Research 86

Expert Panel Validation 86

Contact Us 86

Disclaimer 87

List of Tables

Number of Products under Development for Rhabdomyosarcoma, H1 2015 7

Number of Products under Development for Rhabdomyosarcoma-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Number of Products under Investigation by Universities/Institutes, H1 2015 10

Comparative Analysis by Clinical Stage Development, H1 2015 11

Products under Development by Companies, H1 2015 12

Products under Investigation by Universities/Institutes, H1 2015 13

Rhabdomyosarcoma-Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 14

Rhabdomyosarcoma-Pipeline by Boehringer Ingelheim GmbH, H1 2015 15

Rhabdomyosarcoma-Pipeline by Celgene Corporation, H1 2015 16

Rhabdomyosarcoma-Pipeline by Eisai Co., Ltd., H1 2015 17

Rhabdomyosarcoma-Pipeline by GlaxoSmithKline plc, H1 2015 18

Rhabdomyosarcoma-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 19

Rhabdomyosarcoma-Pipeline by Neotropix, Inc., H1 2015 20

Rhabdomyosarcoma-Pipeline by Novartis AG, H1 2015 21

Assessment by Monotherapy Products, H1 2015 22

Number of Products by Stage and Target, H1 2015 24

Number of Products by Stage and Mechanism of Action, H1 2015 26

Number of Products by Stage and Route of Administration, H1 2015 28

Number of Products by Stage and Molecule Type, H1 2015 30

Rhabdomyosarcoma Therapeutics-Recent Pipeline Updates, H1 2015 58

Rhabdomyosarcoma-Dormant Projects, H1 2015 84

Rhabdomyosarcoma-Discontinued Products, H1 2015 85

List of Figures

Number of Products under Development for Rhabdomyosarcoma, H1 2015 7

Number of Products under Development for Rhabdomyosarcoma-Comparative Analysis, H1 2015 8

Number of Products under Development by Companies, H1 2015 9

Comparative Analysis by Clinical Stage Development, H1 2015 11

Assessment by Monotherapy Products, H1 2015 22

Number of Products by Top 10 Targets, H1 2015 23

Number of Products by Stage and Top 10 Targets, H1 2015 23

Number of Products by Top 10 Mechanism of Actions, H1 2015 25

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 25

Number of Products by Top 10 Routes of Administration, H1 2015 27

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 28

Number of Products by Top 10 Molecule Types, H1 2015 29

Number of Products by Stage and Top 10 Molecule Types, H1 2015 30

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com

Bellicum Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

Celgene Corporation

Eisai Co., Ltd.

GlaxoSmithKline plc

Merrimack Pharmaceuticals, Inc.

Neotropix, Inc.

Novartis AG

Rhabdomyosarcoma Therapeutic Products under Development, Key Players in Rhabdomyosarcoma Therapeutics, Rhabdomyosarcoma Pipeline Overview, Rhabdomyosarcoma Pipeline, Rhabdomyosarcoma Pipeline Assessment

select a license

Single User License
USD 2000 INR 135460
Site License
USD 4000 INR 270920
Corporate User License
USD 6000 INR 406380



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@] kenresearch.com